🇺🇸 FDA
Patent

US 10214522

Anti-alphavbeta1 integrin inhibitors and methods of use

granted A61PA61P1/16A61P11/00

Quick answer

US patent 10214522 (Anti-alphavbeta1 integrin inhibitors and methods of use) held by The Regents of the University of California expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P1/16, A61P11/00, A61P13/12, A61P17/00